Succimer (meso-2,3-dimercaptosuccinic acid (DMSA)) treatment of Andean children with environmental lead exposure

International Journal of Occupational and Environmental Health

Volumn 9, Issue 2, 2003, Pages 164-168

  Counter, S Allen ^a   Ortega, Fernando ^b   Shannon, Michael W ^c   Buchanan, Leo H ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DMSA; Lead; Neurotoxicity; Pediatrics; Succimer

Indexed keywords

LEAD; SUCCIMER; CHELATING AGENT;

ADOLESCENT; ARTICLE; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; ENVIRONMENTAL EXPOSURE; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; LEAD BLOOD LEVEL; LEAD POISONING; PREVENTIVE MEDICINE; PRIORITY JOURNAL; BLOOD; CERAMICS; ECUADOR; OCCUPATIONAL EXPOSURE; PEDIATRICS; PRESCHOOL CHILD;

ADOLESCENT; CERAMICS; CHELATING AGENTS; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; ECUADOR; HUMANS; LEAD; LEAD POISONING, NERVOUS SYSTEM, CHILDHOOD; OCCUPATIONAL EXPOSURE; PEDIATRICS; SUCCIMER;

EID: 0042285713     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2003.9.2.164     Document Type: Article

References (37)

1. Adams RD, Victor M (eds). Principles of Neurology. New York: McGraw-Hill, 1993.
2. Anderson AC, Pueschel SM, Linakis JG. Pathophysiology of lead poisoning. In: Pueschel SM, Linakis JG, Anderson AC (eds). Lead Poisoning in Childhood. Baltimore, MD: Paul H. Brookes, 1996: 75-96.
3. Shannon MW, Townsend MK. Adverse effects of reduced-dose D-penicillamine in children with mild-to-moderate lead poisoning. Ann Pharmacother. 2000; 34: 15-8.
4. Rifai N, Cohen G, Wolf M, et al. Incidence of lead poisoning in young children from inner-city, suburban and rural communities. Ther Drug Monit. 1993; 15: 71-4.
5. National Research Council. Measuring lead exposure in infants, children, and other sensitive populations. Washington, DC: National Academy Press, 1993.
6. Brody DJ, Pirkle JL, Kramer RA, et al. Blood lead levels in the US population. Phase 1 of the Third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1991), JAMA. 1994; 272: 227-83.
7. Aschengrau A, Beiser A, Bellinger D, Copenhafer D, Weitzman M. Residential lead-based-paint hazard remediation and soil lead abatement: their impact among children with mildly elevated blood lead levels. Am J Public Health. 1997; 87: 1698-702.
8. Matte TD, Figueroa PJ, Ostrowski S, et al. Lead poisoning among household members exposed to lead-acid battery repair shops in Kingston, Jamaica. Int J Epidemiol. 1989; 18: 874-81.
9. Counter SA, Buchanan LH, Ortega F, Amarisiriwardena C, Hu H. Environmental lead contamination and pediatric lead intoxication in an Ecuadorian Andean village. Int J Occup Environ Health. 2000; 6: 169-76.
10. Needleman HL, Gunnoc C, Leviton A, et al. Deficits in psychologic and classroom performance of children with elevated dentin lead levels. N Engl J Med. 1979; 300: 689-95.
11. Bellinger D, Leviton A, Waternaux C, Needleman HL, Rabinowitz M. Longitudinal analysis of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med. 1987; 316: 1037-43.
12. Dietrich KN, Succop PA, Bornschein RL, et al. Lead exposure and neurobehavioral development in later infancy. Environ Health Perspect. 1990; 89: 13-9.
13. Dietrich KN, Succop PA, Bornschein OG, Keith RW. Lead exposure and the central auditory processing abilities and cognitive development of urban children: the Cincinnati lead study cohort at age 5 years. Neurotoxicol Teratol. 1992; 14: 51-6.
14. Shannon MW, Graef JW. Lead intoxication in infancy. Pediatrics. 1992; 89: 87-90.
15. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds). Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill 1994.
16. Banks EC, Ferretti LE, Shucard DW. Effects of low level lead exposure on cognitive function in children: a review of behavioral, neuropsychological and biological evidence. Neurotoxicology. 1997; 18: 237-81.
17. Pirkle JL, Brody DJ, Gunter EW, et al. The decline in blood lead levels in the United States. JAMA. 1994; 272: 284-91.
18. Ruff HA, Markowitz ME, Bijur PE, Rosen JF. Relationships among blood lead levels, iron deficiency, and cognitive development in two year-old children. Environ Health Perspect. 1996; 104: 180-5.
19. Washerman GA, Liu X, Popavac D, et al. The Yugoslavia prospective lead study: contributions of prenatal and postal lead exposure to early intelligence. Neurotoxicol Teratol. 2000; 22: 811-8.
20. Counter SA, Buchanan LH, Rosas HD, Ortega F. Neurocognitive effects of chronic elevated blood lead levels in Andean children. J Neurol Sci. 1998; 160: 47-53.
21. Counter SA, Buchanan LH, Ortega F, Rifia N., Blood lead and hemoglobin levels in Andean children with chronic lead intoxication. Neurotoxicology. 2000; 21: 301-8.
22. Wegmann K. Chelation therapy to treat lead toxicity in children. Minn Med. 1992; 75: 25-7.
23. Graziano JH. Conceptual and practical advances in the measurement and clinical management of lead toxicity. Neurotoxicology. 1993; 14: 219-23.
24. Liebelt EL, Shannon MW. Oral dictators for childhood lead poisoning. Pediatr Ann. 1994; 23: 616-9.
25. Chisolm JJ. Mobilization of lead by calcium disodium edetate: a reappraisal. Arch Pediatr Med. 1987; 141: 1256-7.
26. Chisolm JJ. Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures. Environ Health Perspect. 1990; 89: 67-74.
27. Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med. 1999; 130: 7-13.
28. Chisolm JJ. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Pharmacol Clin Toxicol. 1992; 30: 493-504.
29. Glotzer DE. The current role of 2,3-dimercaptosuccinic acid (DMSA) in the management of childhood lead poisoning. Drug Saf. 1993; 9: 85-92.
30. Anderson RL, Super DM. Short-term efficacy of oral dimercaptosuccinic acid in children with low to moderate lead intoxication. Pediatrics. 1995; 96: 683-7.
31. Besunder JB, Super DM, Anderson RL Comparison of dimercaptosuccinic acid and calcium disodium ethylenediaminetetraacetic acid versus dimercaptopropanol and ethylenediaminetetraacetic acid in children with lead poisoning. J Pediatr. 1997; 130: 966-71.
32. O'Connor ME, Rich D. Children with moderately elevated lead levels: is chelation with DMSA helpful? Clin Pediatr. 1999; 38: 325-31.
33. Bornschein RL, Chisolm JJ, Damokosh AI, et al. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 μg/dL. Treatment of lead exposed children (TLC) trial group. Pediatr Res. 2000; 48: 593-9.
34. Cremin JJ, Luck M, Laughlin N, Smith DR. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. Toxicol Appl Pharmacol. 1999; 161: 283-93.
35. Smith D, Bayer L, Strupp BJ. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model. Environ Res. 78: 1998; 168-76.
36. Smith DR, Calacsan C, Woolard D, Luck M, Cremin J, Laughlin NK. Succimer and the urinary excretion of essential elements in a primate model of childhood lead exposure. Toxicol Sci. 2000; 54: 473-80.
37. Chisolm JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Pharmacol Clin Toxicol. 38: 2000; 365-75.